Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Bronchiolitis Obliterans Syndrome Market Size Forecast: How Big Could The Market Get By 2030?
The market size for bronchiolitis obliterans syndrome has experienced substantial growth in recent years. This market is forecast to expand from $1.59 billion in 2025 to $1.73 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.1%. The expansion observed in previous periods can be linked to factors such as an increase in organ transplantations, instances of chronic graft rejection, advancements in hospital pulmonary care, the application of immunosuppressants, and the scarcity of early diagnostic methods.
The market for bronchiolitis obliterans syndrome is anticipated to experience robust expansion over the coming years. It will grow to $2.43 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. This projected growth is driven by factors such as an increase in transplant procedures, advancements in early detection technologies, the development of personalized immunotherapy, the establishment of specialty respiratory centers, and enhanced long-term patient management strategies. Key developments expected during this period involve more intensive monitoring following transplantation, the rise of immunosuppressive therapies, wider availability of early diagnostic tests, a strong emphasis on preserving long-term lung function, and an increasing need for specialized pulmonary care services.
Get A Free Sample Report With In-Depth Market Insights:
Bronchiolitis Obliterans Syndrome Market Industry Drivers: What’s Behind The Revenue Growth?
The expansion in lung transplant procedures is anticipated to fuel the progression of the bronchiolitis obliterans syndrome market in the coming years. A lung transplantation involves replacing a diseased or non-functional lung with a healthy one from a donor to enhance respiratory function. The rise in lung transplants stems from innovations in surgical methods, which have considerably boosted success rates and minimized adverse effects, making the operation safer and more readily available for patients requiring it. For advanced bronchiolitis obliterans syndrome, lung transplantation serves as an effective treatment, substituting damaged lungs with healthy donor lungs to improve breathing and overall lung function. For instance, in January 2025, according to the Organ Procurement and Transplantation Network, a US-based non-profit scientific and educational organization, lung transplants had the largest proportional growth from 3,026 transplants in 2023 to 3,340 in 2024, an increase of 10.4 percent. Consequently, the increasing volume of lung transplants is propelling the expansion of the bronchiolitis obliterans syndrome market.
Bronchiolitis Obliterans Syndrome Market Segments: Where Is Growth Concentrated?
The bronchiolitis obliterans syndrome market covered in this report is segmented –
1) By Treatment Type: Medication, Oxygen Therapy, Lung Transplant
2) By Diagnosis: Pulmonary Function Tests, Imaging Tests, Lung Biopsy, Other Diagnosis
3) By Disease Type: Acute Bronchiolitis, Chronic Bronchiolitis Obliterans Syndrome
4) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users
Subsegments:
1) By Medication: Immunosuppressants, Corticosteroids, Antibiotics, Bronchodilators, Anti-Inflammatory Agents
2) By Oxygen Therapy: Continuous Oxygen Therapy, Intermittent Oxygen Therapy, Portable Oxygen Therapy, Hyperbaric Oxygen Therapy
3) By Lung Transplant: Single Lung Transplant, Double Lung Transplant, Living Donor Lung Transplant, Retransplantation
#Bronchiolitis Obliterans Syndrome Market Growth Trends: What’s Shaping The Future Outlook?
Leading companies operating within the bronchiolitis obliterans syndrome market are concentrating on creating sophisticated solutions, such as home-based nebulized therapy, to improve medication compliance and impede disease advancement through precise, ongoing treatment. This at-home nebulized therapy involves the utilization of a nebulizer to convert liquid medicine into a fine breathable mist, facilitating direct application to the lungs. This convenient, self-administered approach enables effective management of respiratory ailments from the comfort of one’s residence. For instance, in March 2023, Renovion, Inc., a US-based clinical-stage pharmaceutical firm, introduced ARINA-1, which was granted Food and Drug Administration (FDA) Fast Track Designation for its objective of preventing the progression of bronchiolitis obliterans syndrome (BOS) in individuals who have undergone bilateral lung transplants. This significant regulatory achievement highlights ARINA-1’s capacity to address a crucial unmet medical requirement in the field of transplant medicine. The Fast Track status allows for more frequent interactions with the FDA and gives ARINA-1 priority for expedited development and review, showcasing Renovion’s dedication to promoting respiratory health through groundbreaking, patient-centric treatments.
Bronchiolitis Obliterans Syndrome Market Key Participants And Competitive Landscape
Major companies operating in the bronchiolitis obliterans syndrome market are Novartis AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, AstraZeneca plc, Sanofi S.A., Johnson & Johnson (Janssen), AbbVie Inc., Bristol-Myers Squibb Company, Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals Incorporated, United Therapeutics Corporation, Insmed Incorporated, Viatris Inc., Zydus Lifesciences Ltd., Cadila Pharmaceuticals Ltd.
View The Full Bronchiolitis Obliterans Syndrome Market Report:
Bronchiolitis Obliterans Syndrome Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the bronchiolitis obliterans syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bronchiolitis obliterans syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model